Cargando…

Opioids and oral P2Y12 receptor inhibitors: A drug–drug interaction

Detalles Bibliográficos
Autor principal:	Kubica, Jacek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Via Medica 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550322/ https://www.ncbi.nlm.nih.gov/pubmed/36196657 http://dx.doi.org/10.5603/CJ.2022.0082

Ejemplares similares

Personalized antiplatelet therapy with P2Y(12) receptor inhibitors: benefits and pitfalls
por: Winter, Max-Paul, et al.
Publicado: (2015)

Pharmacokinetic/pharmacodynamic modeling of drug interactions at the P2Y(12) receptor between selatogrel and oral P2Y(12) antagonists
por: Henrich, Andrea, et al.
Publicado: (2021)

Pretreatment with P2Y(12) Receptor Inhibitors in Acute Coronary Syndromes—Is the Current Standpoint of ESC Experts Sufficiently Supported?
por: Niezgoda, Piotr, et al.
Publicado: (2023)

Opioids and Their Receptors: Present and Emerging Concepts in Opioid Drug Discovery
por: Spetea, Mariana, et al.
Publicado: (2020)

Opioids and Their Receptors: Present and Emerging Concepts in Opioid Drug Discovery II
por: Van Rijn, Richard M., et al.
Publicado: (2022)

To Pretreat or Not to Pretreat (With Oral P2Y12 Antagonists)? That is the Question
por: Lowenstern, Angela, et al.
Publicado: (2017)

Prescribing opioids and psychotropic drugs in pregnancy
por: Patrick, Stephen W, et al.
Publicado: (2017)

LIGAND-RECEPTOR INTERACTIONS AND DRUG DESIGN
por: Zhang, Yanling, et al.
Publicado: (2015)

Pharmacokinetic Drug–Drug Interactions and Herb–Drug Interactions
por: Choi, Min-Koo, et al.
Publicado: (2021)

Newer P2Y(12) Inhibitors: How Does the Interventional Cardiologist Choose?
por: Shavelle, David M.
Publicado: (2016)

Antipsychotic Drugs Inhibit Platelet Aggregation via P2Y(1) and P2Y(12) Receptors
por: Wu, Chang-Chieh, et al.
Publicado: (2016)

Opioid Receptors and Protonation-Coupled Binding of Opioid Drugs
por: Lešnik, Samo, et al.
Publicado: (2021)

Does ticagrelor effectively inhibit platelets in patients undergoing mild therapeutic hypothermia or it does not?
por: Kubica, Jacek
Publicado: (2022)

Drug Interactions With New Synthetic Opioids
por: Pérez-Mañá, Clara, et al.
Publicado: (2018)

Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor
por: Mendell, Jeanne, et al.
Publicado: (2013)

ISAR-REACT 5 — What have we learned?
por: Kubica, Jacek, et al.
Publicado: (2019)

Opioid Drug-Drug-Drug Interactions and Unintentional Traumatic Injury: Screening to Detect Three-Way Drug Interaction Signals
por: Acton, Emily K., et al.
Publicado: (2022)

Epigenetic Modulation of Opioid Receptors by Drugs of Abuse
por: Reid, Ke Zhang, et al.
Publicado: (2022)

Peripheral Opioid Receptor Antagonists for Opioid-Induced Constipation: A Primer on Pharmacokinetic Variabilities with a Focus on Drug Interactions
por: Gudin, Jeffrey, et al.
Publicado: (2020)

Cobicistat: A case of mislabelled drug‐drug interaction risk?
por: Burger, David M., et al.
Publicado: (2020)

The Use Pattern and Clinical Impact of Novel P2Y12 Receptor Antagonists for Acute Myocardial Infarction in Korea
por: Kim, Soo-Joong
Publicado: (2017)

Drug-drug interactions with direct-acting antivirals — less is more
por: Wong, Grace Lai-Hung
Publicado: (2021)

Drug–drug Interactions: An Overlooked Dimension of the COVID-19 Pandemic
por: Beninger, Paul
Publicado: (2023)

Linezolid/unspecified opioids interaction: Serotonin syndrome following drug-drug interaction: case report
Publicado: (2022)

P2Y12 inhibitors for the neurointerventionalist
por: Borchert, Robin J, et al.
Publicado: (2021)

Unguided De-Escalation Strategy From Potent P2Y(12) Inhibitors in Patients Presented With ACS: When, Whom and How?
por: Park, Jin Sup, et al.
Publicado: (2022)

Ticagrelor: The First Reversibly Binding Oral P2Y(12) Receptor Antagonist
por: Husted, Steen, et al.
Publicado: (2009)

False-Positive Versus True-Positive Drug-Drug Interactions With Warfarin
por: Curtiss, Frederic R.
Publicado: (2006)

Adverse Reactions to Anticancer Drugs in the Oral Cavity
por: Di Fede, Olga, et al.
Publicado: (2018)

Prescribing issues in older adults living with HIV: thinking beyond drug–drug interactions with antiretroviral drugs
por: Livio, Françoise, et al.
Publicado: (2019)

Comparative Effectiveness and Safety of Oral P2Y12 Inhibitors in Patients on Chronic Dialysis
por: Jain, Nishank, et al.
Publicado: (2021)

The United States Drug Enforcement Administration and Prescription Opioid Production Quotas: An End Game of Eradication?
por: Schatman, Michael E, et al.
Publicado: (2020)

Drug–Drug Interactions with Direct Oral Anticoagulants
por: Foerster, Kathrin I., et al.
Publicado: (2020)

The effects of P2Y(12) adenosine receptors’ inhibitors on central and peripheral chemoreflexes
por: Tubek, Stanislaw, et al.
Publicado: (2023)

Transporter-Mediated Drug–Drug Interactions with Oral Antidiabetic Drugs
por: Klatt, Sabine, et al.
Publicado: (2011)

Special Issue on Drug–Membrane Interactions
por: Pinheiro, Marina
Publicado: (2021)

A Physiologically Based Pharmacokinetic Model to Predict Potential Drug–Drug Interactions and Inform Dosing of Acumapimod, an Oral p38 MAPK Inhibitor
por: Agyemang, Alex, et al.
Publicado: (2020)

Predictive Modelling of Susceptibility to Substance Abuse, Mortality and Drug-Drug Interactions in Opioid Patients
por: Vunikili, Ramya, et al.
Publicado: (2021)

Oxygen: A Stimulus, Not “Only” a Drug
por: Balestra, Costantino, et al.
Publicado: (2021)

Application of a microdosed cocktail of 3 oral factor Xa inhibitors to study drug–drug interactions with different perpetrator drugs
por: Mikus, Gerd, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pqc8s237hfct096iho69qf6scj